Pharmacological role and clinical applications of interleukin-6 in rheumatoid disease

Pierre Youinou1,2, Sophie Hillion1,2, Gabriel J Tobón1,2, Divi Cornec1,2, Jacques-Olivier Pers1,2, Alain Saraux1,2, Boutahar Bendaoud1,2, Yves Renaudineau1,2, Christophe Jamin1,2
1Université Européenne de Bretagne and Université de Brest, “Immunology and Pathology”, 2ScInBioS, Brest, France; University Medical School Hospital, Brest, France

Abstract: Interleukin (IL)-6 is a pleiotropic cytokine that promotes polyclonal activation of B lymphocytes. This implies that its deregulation favors inflammatory conditions. Through the association of the transducing glycoprotein 130 with the membrane-anchored receptor (R) α, IL-6 can generate functionally distinct signals. Given these particular molecular aspects, numerous activities ascribed to this cytokine are, in fact, due to the insertion into soluble IL-6Rα. The system is instrumental in rheumatoid arthritis (RA), Sjögren’s syndrome and systemic lupus erythematosus (SLE). In this respect, it is interesting that the expression of the recombination-activating gene is sustained by IL-6 in B lymphocytes, and repressed by anti-IL-6R antibody (Ab) in RA and SLE. Agents that inhibit IL-6 signaling have now entered clinical trials. As expected, clinical benefits are reported in the treatment of autoimmune disorders with anti-IL-6R Ab, but other perspectives remain open in the forthcoming biotherapies of immune-mediated disorders.

Keywords: interleukin-6, B lymphocyte, rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, biotherapy

Over the past few years, a number of mediators have been reported as different factors, and characterized independently as potently active for inducing B cell growth and differentiation. These include the T cell replacing factor, the B cell stimulatory factor-2, the macrophage-derived survival agent, the myeloid differentiation proteins and the hepatocyte-stimulating cytokine. Progressively, the evidence went to prove that they duplicated each other, and the whole of them appeared to resemble interferon –P2 (IFN-β2) so much, that it made sense to designate all these mediators as interleukin 6 (IL-6). Besides such amalgamation, the IL-6 set of cytokines encompasses, among others, the leukemia inhibitory factor (LIF), the ciliary neurotrophic factor, the IL-11, the cardiotrophin-1, and the cardiotrophin-like factors.1 Concomitant with such a bloom of ligands (Table 1), elucidation on the molecular mechanisms underlying this issue has yielded a first complementary DNA for the 80 kDa IL-6 binding α chain, and a second for the 130 kDa IL-6 signal transducing β chain.2,3 Two specimens of the former receptor chains (R) Rα associate with two of the latter glycoprotein gp130. Given that the resulting tetramer retains two molecules of IL-6, the plasma membrane is ultimately decorated with an hexamer.4

Once the complex of two IL-6 Rα chains, two specimens of gp130 and two molecules of IL-6 has been constructed, the cytokine included within the aggregate acquires the capacity to exert a variety of biological activities. The mechanisms operate in autocrine, paracrine and endocrine manners in wide-spread organs. The function of IL-6 was originally considered to be confined to the promotion of
immunoglobulin (Ig) release, but this has been extended to pro- and anti-inflammatory properties. Not only does it affect the immune system, but it orchestrates numerous other biological systems. Nevertheless, for B cells to proliferate and differentiate, IL-6 presents as an absolute requisite.5

This fundamental requirement shows this cytokine is central to the pathophysiology of B lymphocyte mediated systemic diseases. Uncontrolled overproduction of IL-6 appears to be responsible for the clinical symptoms and biological abnormalities of rheumatoid arthritis (RA), primary Sjögren’s syndrome (pSS) and systemic lupus erythematosus (SLE). Insights have subsequently been gained into the relationship between IL-6, IL-17, and the IL-23 class of cytokines and the B cell activating factor of the tumor necrosis factor (TNF) family (BAFF) on the one side, and into the interdependence between B effector (Be) cell and T helper (Th) cell subset, on the other side.6–8 These stimulators of the synthesis of acute phase proteins by hepatocytes proceed from a number of cells, along with IL-1β, IL-8, TNFα, and transforming growth factor-β (TGFβ). Such discoveries have revolutionized our view about the pathophysiology of autoimmune diseases.

New technologies have brought a wealth of information about the role of respective T and B cell subsets throughout the inflammatory process. One consequence of this current revolution of biotherapies is that IL-6 is being converted into a grade one therapeutic target in the setting of immune mediated diseases.9 The rationale for its blockade consists of interfering with B cell functions, because B lymphocyte has recently moved to the center of the autoimmunity stage.10 In this respect, various antagonists of IL-6Rα, most particularly antibodies (Abs), have shown considerable promise for the treatment of nonorgan-specific autoimmune disorders.11

**Immunopathology of interleukin-6**

**Production of interleukin-6**

IL-6 derives not only from immune cells, such as monocytes, macrophages, T and B lymphocytes, and polymorphonuclear cells (PMNs), but also from a variety of other cell types, such as fibroblasts, epidermal keratinocytes, adipocytes, hepatocytes, renal mesangial cells, and syncytiotrophoblasts.12 In addition, several tumor cell types generate IL-6, including plasmacytoma, multiple myeloma, and renal carcinoma cells. Among T lymphocytes, the synthesis of IL-6 is restricted to those polarized towards Th2, while, among B lymphocytes, it is restricted to those polarized towards Be2.13,14

**The cells impacted by interleukin-6**

Proteases cleave the membrane anchored IL-6Rα, which is subsequently shed into the blood. The circulating cytokine binds to the IL-6Rα membrane or to its cell-free form.

This association between the ligand and its receptor is not enough to launch the downstream cascade of immunological events. The soluble complex of IL-6 and IL-6Rα binds to the membrane gp130, but not to the membrane IL-6Rα. Indeed, the contribution of IL-6Rβ is necessary to mediate signaling into cells (Figure 1). The IL-6Rα is specific for hepatocytes, monocytes, PMNs, T and B lymphocyte subsets, whereas the IL-6Rβ is expressed by those cells and other body cells as well.15 Furthermore, the latter signal transducer is shared by LIF, IL-11, IL-12, IL-23, and so forth. The cascade is triggered off by this β chain, once the cytokine has bound to its cognate α chain receptor, so the ensuing events are specific for this cytokine.

Complexes of IL-6 and IL-6Rα fit into the IL-6Rβ.16 The process is unique, and the term “transsignaling” has been coined by Jones and colleagues to indicate this phenomenon.17 It raises the possibility that IL-6Rα devoid cells become responsive to IL-6, even though activities to IL-6 are mediated by soluble IL-6Rα, once the complexes have been retained by gp130.18 The model is supported by the conclusions of epitope mapping analyses that yield distinct sites. Alternatively, in the absence of IL-6, insoluble IL-6Rα may be able to adhere to an hitherto unidentified receptor. Its endeavor covers local induction of intercellular adhesion molecules, production of supplemental pro-inflammatory cytokines, and recruitment of leukocytes to disease sites.18

In brief, as highlighted by Jones, IL-6 has the capacity to orchestrate transition from innate inflammatory response to acquired immunity, as suggested but the early classification of IL-6 as a differentiation factor for T and B lymphocytes.19 Supporting this concept, poly (I-C), followed by muramyl dipeptide, up-regulates IL-6 and IL-8 in RA fibroblasts through activation of Toll-like receptors (TLR) TLR-2, TLR-3 and TLR-4 in culture.20
IL-6 signal transduction
Once transduced downstream from the transmembrane receptor, the signal activates Janus tyrosine kinase (JAK) family members (Figure 2). There are four members of the JAK family, of which JAK1, JAK2 and tyk2 constitutively associate with gp130. The sequence ends with the activation of signal transducer and activator (STAT) STAT1 and STAT3, and the translocation of these transcription factors from the cytoplasm to the nucleus.21 Other tyrosine residues of gp130 are recognized by the SH2-containing protein tyrosine phosphatase 2 and the subsequent cascade of extracellular signal-regulated and mitogen activated protein kinases. Two suppressors of cytokine signaling (SOCS), SOCS1 and SOCS3, turn off the effects mediated by the IL-6 family of cytokines.22

The cytokine network
Generation of IL-17, producing Th17, despite its dependence on IL-23, requires only TGFβ plus IL-6, which is thus inserted into a cytokine network.23 The release of IL-17 by the Th17 CD4+ T lymphocytes is dependent on dendritic cell cytokines.6 Among these mediators, IL-23 is necessary for IL-6, and, given the absence of Th17 cells in IL-6-deficient mice, this second cytokine is not dispensable for evolution of naïve CD4+ T lymphocytes into Th17 cells.24

Is IL-6 relevant to autoimmunity?
Rheumatoid arthritis
The casual discovery of high levels of IL-6, associated with efflorescence of Abs in patients with cardiac myxoma was unexpected, and became the first clue as to whether IL-6 might be central to autoimmunity.25 Investigators verified whether such was the case in conventional autoimmune diseases, and indeed the production of IL-6 by RA activated synoviocytes was elevated, compared with that of synoviocytes of patients with osteoarthritis. High amounts of IL-6 were detected in synovial fluid from the joints of RA patients.

The mediator contributes to cartilage and bone destruction in RA, so that IL-6-deficient mice backcrossed to a susceptible genetic background resist collagen-induced arthritis (CIA).26

Primary Sjögren’s syndrome
Whereas, the IL-6 levels in circulation stays low under normal conditions, its synthesis is up-regulated in patients
with pSS. Consequently, serum and saliva levels of IL-6 are elevated, messenger RNAs for IL-6 become detectable in their salivary glands, and the frequency of IL-6 secreting cells is markedly increased in their peripheral blood.\textsuperscript{27,28}

Locally, too much IL-6 is released by epithelial cells of the glands, and an increased proportion of infiltrating lymphocytes produce IL-6 in pSS. Consistent with this view, inflammation has been implicated in polyclonal B cell activation and monoclonal B cell neoplasia in these patients. A handful of cytokines have been found to differ between patients and controls.\textsuperscript{29} These include IL-1\textsubscript{β}, IL-6, IL-8, IL-12, TNF-\textalpha and BAFF.\textsuperscript{30}

**Systemic lupus erythematosus**

Similarly, B cells from patients with SLE express spontaneously high levels of IL-6, and harbor receptors for IL-6.\textsuperscript{30} These findings suggest that the scenario is autocrine, and that part of the B cell hyperactivity is independent of T cell assistance. Some researchers claim that urinary IL-6 denotes lupus proliferative glomerulonephritis.\textsuperscript{31} This may be ascribed to infiltrating inflammatory cells, as the major source of IL-6 in the kidney of patients with lupus nephritis.\textsuperscript{32}

Early data found IL-6 to be a strong inducer of B cell differentiation into IgG-secreting plasma cells. In the context of SLE, later studies established that, apart from IL-6, no other cytokine is capable of directly triggering the anti-double-stranded (ds) DNA Ab production.\textsuperscript{33} Conversely, incubation of SLE B cells with anti-IL-6 and/or anti-IL-6R Abs reduces total IgG production, as well as that of anti-dsDNA Ab, in a dose dependent manner.\textsuperscript{34}

**Miscellaneous**

Overproduction of IL-6 has then been described in a number of autoimmune settings (myasthenia gravis, multiple sclerosis, systemic-onset juvenile idiopathic arthritis, and insulin dependent diabetes mellitus), a variety of inflammatory conditions (asthma, septic shock, stress, and inflammatory bowel diseases), and a handful of neoplastic disorders (colon cancer, multiple myeloma, head and neck squamous cell carcinoma, and B cell malignancies).\textsuperscript{35,36}

Plasma IL-6 levels increase with advancing age, due to age-associated diseases, and to the fact that sex hormones, known to repress IL-6 expression, diminish with age.

**IL-6-targeted treatments**

**The basic mechanisms**

The ability of IL-6 to induce the maturation and differentiation of the cells is consistent with some form of epigenetic
control over the differentiation process. The most efficient way to silence a gene is to transfer methyl groups to cytosine-phosphate-guanosine motifs in their promoter by the DNA methyltransferase (DNMT) family, where DNMT1 is a maintenance methylase. 27 In the absence of changes in total cyclin or cyclin E-dependent kinase expression in SLE, the abnormalities should rely on IL-6 mediated cell cycle arrest at the G0/G1 interface. Thus, IL-6-induced cell cycle arrest blocks the action of DNMTs and thereby renders any methylation induced repression of the IL-6 gene impossible. 38 IL-6 protein in excess transactivates the expression of the DNMT1 promoter by regulating transcription of the Friend leukemia virus integration protein, FLI-1, which is one of its transcription factors. 39

**Perspectives in biotherapy**

As that of other cytokines, the paradigm of IL-6 has recently been shifted from basic science to therapeutic medicine, and valuable strategies have been recently launched for inflammatory diseases (Table 2). Although anti-IL-6 seems most appropriate as a target for therapy, accumulation of IL-6 in the form of monomeric immune complexes has been observed, following injection of the mAb against the cytokine into the animals. 40,41

Hence, it stands to reason that to substitute anti-IL6 mAb with anti-IL-6R mAb that blocks the transmembrane, as well as the soluble forms of IL-6R, is the most logical strategy to be efficient. 42 Clinical benefits have recently been obtained in RA. The Study of Active Monotherapy used for RA IL-6 inhibitor (referred to as the “SAMURAI trial”), has shown limitation of radiographic progression, as compared with conventional disease modifying anti-rheumatic drugs. 43 Furthermore, rapid and sustained improvement in bone and cartilage turnover markers with tocilizumab (TZM) plus methotrexate has been observed in RA patients with an adequate response to methotrexate. 44 TZM is a humanized anti-human IL-6R Ab recently developed in Japan. This mAb binds to the α chain of the membrane-bound and cell-free receptor. Although its safety profile has not been fully defined, this agent has been shown to prevent structural joint damages. It induced rapid, marked, and dose dependent reductions in the levels of biochemical markers of cartilage which are N-terminal propeptide of type IIA, collagen helical peptide and matrix metalloproteinase 3, providing evidence of a beneficial effect on bone turnover. Parallel trials may help the decision making process, but Maini and the CHARISM A study group, for the Chugai humanized anti-human recombinant IL-6 mAb have also reported on the efficacy of TZM in 359 patients with RA. 45

Similar success has been obtained in systemic-onset juvenile idiopathic arthritis, Castleman’s disease (a similar condition to pSS), and Crohn’s disease (a chronic inflammatory bowel disease of unknown etiology). 46–48 No differences have been shown in the incidence of adverse events between the patients who received placebo and those who received TZM. 49

One may also envision IL-6-related trials in other inflammatory disorders, including ankylosing spondylitis and psoriasis. Still to be established, are whether transition from acute to chronic inflammation occurs in relation with a breakdown in the IL-6 control, and to decipher the interplay of endothelial growth factor β and other cytokines with IL-6.

**Conclusion**

Progress in the study of IL-6 has generated innovative concepts. 13 IL-6 is indeed a particular case of signal transduction and serves as the signal orchestration model. Recent advances have been made in mapping the immunopathophysiology of this cytokine, so are we likely to learn about autoimmune diseases, and IL-6-regulated tumors where targets for anti-IL-6 R therapy might also be expanded. 26,50 Furthermore, the antagonists for IL-6 might be associated with those for BAFF.

One area of consideration is the question of whether TZM has a better risk-benefit balance than established mAbs. However, some investigators believe that this agent could well become a first-line therapy in RA and related systemic autoimmune diseases.

---

**Table 2 Perspectives in therapy with anti-interleukin (IL-6) or anti-IL-6 receptor antibody**

<table>
<thead>
<tr>
<th>Autoimmune diseases</th>
<th>Other inflammatory conditions</th>
<th>Other disease states</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatoid arthritis</td>
<td>Castleman’s disease</td>
<td>Septic shock</td>
</tr>
<tr>
<td>Primary Sjögren’s syndrome</td>
<td>Crohn’s disease</td>
<td>Multiple myeloma</td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td>Ashma</td>
<td>B cell malignancies</td>
</tr>
<tr>
<td>Hashimoto thyroiditis (unpublished)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic-onset juvenile idiopathic arthritis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myasthenia gravis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Acknowledgments

Thanks are due to Simone Forest and Geneviève Michel for their help with the typing of the manuscript and to the artist, Simone Forest, for assistance.

Disclosures

The authors report no conflicts of interest in this work.

References


